Filing Details

Accession Number:
0001104659-17-064383
Form Type:
13G Filing
Publication Date:
2017-10-27 17:00:24
Filed By:
Abbvie Inc.
Company:
Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
Filing Date:
2017-10-27
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
AbbVie Inc 924,662 0 924,662 0 924,662 4.84%
Filing

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, DC 20549

 

 

 

 

SCHEDULE 13G/A

(Amendment No. 1)

 

Under the Securities Exchange Act of 1934

ENANTA PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

29251M106

(CUSIP Number)

October 17, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o

Rule 13d-1(b)

o

Rule 13d-1(c)

x

Rule 13d-1(d)

 


 

CUSIP No.: 29251M106

 

 

1

Names of Reporting Persons:
AbbVie Inc.

 

 

2

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

o

 

 

(b)

o

 

 

3

SEC Use Only

 

 

4

Citizenship or Place of Organization:
State of Delaware

 

 

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

5

Sole Voting Power:
924,662

 

6

Shared Voting Power:
0

 

7

Sole Dispositive Power:
924,662

 

8

Shared Dispositive Power:
0

 

 

9

Aggregate Amount Beneficially Owned by Each Reporting Person:
924,662

 

 

10

Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o

 

 

11

Percent of Class Represented by Amount in Row 9:
4.84 (1)

 

 

12

Type of Reporting Person (See Instructions):
CO

 


(1) This percentage is calculated based upon 19,090,383 shares of the Issuers Common Stock outstanding as of August 1, 2017, as set forth in Issuers Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017, filed with the Securities and Exchange Commission on August  9, 2017.

 

2


 

Item 1(a).

Name of Issuer:
Enanta Pharmaceuticals, Inc.

Item 1(b).

Address of Issuers Principal Executive Offices:
500 Arsenal Street
Watertown, Massachusetts 02472

 

Item 2(a).

Name of Person Filing:
AbbVie Inc.

Item 2(b).

Address of Principal Business Office or, if none, Residence:
1 North Waukegan Road
North Chicago, Illinois 60064-6400

Item 2(c).

Citizenship:
Not applicable.

Item 2(d).

Title of Class of Securities:
Common Stock

Item 2(e).

CUSIP Number:
29251M106

 

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)

o

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

 

(b)

o

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

 

(c)

o

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

 

(d)

o

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

 

(e)

o

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

 

(f)

o

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

(g)

o

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

 

(h)

o

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

(i)

o

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

(j)

o

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); and

 

(k)

o

Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with

§ 240.13d1(b)(1)(ii)(J), please specify the type of institution:____________________________.

 

3


 

Item 4.

Ownership.

Item 4(a)

Amount beneficially owned:   

924,662 shares

Item 4(b)

Percent of class:   

4.84 (1)

Item 4(c)

Number of shares as to which such person has:

 

 

 

(i)

Sole power to vote or to direct the vote:   

924,662 shares

 

 

(ii)

Shared power to vote or to direct the vote:    

0

 

 

(iii)

Sole power to dispose or to direct the disposition of:   

924,662 shares

 

 

(iv)

Shared power to dispose or to direct the disposition of:   

0

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.   x

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

 

All securities reported in this schedule are owned by the Reporting Person.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

 

Not applicable.

 

Item 8.

Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not applicable.

 


(1) This percentage is calculated based upon 19,090,383 shares of the Issuers Common Stock outstanding as of August 1, 2017, as set forth in Issuers Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017, filed with the Securities and Exchange Commission on August 9, 2017.

 

4


 

Item 10.

Certifications.

 

Not applicable.

 

SIGNATURES

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: October 27, 2017

 

 

ABBVIE INC.

 

 

 

By:

/s/ William J. Chase

 

Name:

William J. Chase

 

Title:

Executive Vice President, Chief Financial Officer

 

 

 

5